List of Dyanavel Xr 10 drug patents

Dyanavel Xr 10 is owned by Tris Pharma Inc.

Dyanavel Xr 10 contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.

Dyanavel Xr 10 has a total of 3 drug patents out of which 0 drug patents have expired.

Dyanavel Xr 10 was authorised for market use on 04 November, 2021.

Dyanavel Xr 10 is available in tablet, extended release;oral dosage forms.

The generics of Dyanavel Xr 10 are possible to be released after 15 March, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic